Aditxt and Evofem partner to launch endometriosis diagnostic in 2025 [Yahoo! Finance]
Aditxt, Inc. (ADTX)
Company Research
Source: Yahoo! Finance
As part of the agreement, the companies will develop a marketing strategy and commercialisation plan for launching Pearsanta's Mitomic endometriosis test (MET) in the US in mid-2025. Evofem also plans to potentially expand its women's health portfolio with tests developed by Aditxt's subsidiary Pearsanta, including a Mitomic ovarian test for early detection of ovarian cancer. “We look forward to leveraging our strong relationships with OB/GYNs and allied healthcare providers to plan and execute the successful US launch of this first-in-class non-invasive diagnostic,” said Evofem's CEO Saundra Pelletier. Pearsanta's MET detects a specific deletion in mitochondrial DNA, a novel and proprietary biomarker for endometriosis. The company noted that it has evaluated MET in "over 300 endometriosis cases" and plans to validate the product in 600 cases. Pearsanta added the MET product to its portfolio earlier this year as part of the $25m acquisition of MDNA Life Sciences. Along with the
Show less
Read more
Impact Snapshot
Event Time:
ADTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADTX alerts
High impacting Aditxt, Inc. news events
Weekly update
A roundup of the hottest topics
ADTX
News
- Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024Business Wire
- Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt [Yahoo! Finance]Yahoo! Finance
- Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by AditxtBusiness Wire
- Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025Business Wire
- Aditxt and Evofem amend merger agreement [Seeking Alpha]Seeking Alpha
ADTX
Sec Filings
- 9/23/24 - Form 8-K
- 9/16/24 - Form 424B3
- 9/16/24 - Form EFFECT
- ADTX's page on the SEC website